SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing ...
MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha(R) (evolocumab injection) for eligible ...
Mets vs. Giants preview for April 2, 2026, including expert predictions, best bet, hitter projections, and top BetMGM player ...
Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares ...
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study ...
PuraPly® AM is a patent-protected product that is differentiated among all skin substitutes by combining a native, cross-linked collagen matrix with polyhexamethylene biguanide (PHMB) antimicrobial to ...
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...
Paris, April 8, 2026 — Clariane (CLARI.PA – ISIN FR0010386334) announces today that it has launched an offering (the “ Offering ”) of €500 million in aggregate principal amount of new euro-denominated ...
The transaction includes intellectual property- customer-related assets and commercial operations, positioning the Company for the next stage of its strategy Further strategic update to follow shortly ...
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of ...
VANCOUVER, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) -- (TSXV: PTF): Pender Growth Fund Inc. (the 'Company” or 'PTF”) is pleased to announce that PTF’s holding, Pender Software Holdings Ltd. ( ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted ...